The telitacicept 80 mg exhibited a significantly greater increase in C4 compared with the placebo group at week 48 as well, while the difference in the change in C3 did not reach statistical significance ( figure 5D,E ).
← all excerpts
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
1
—
—